{"result": "(\"entity\"<|>FEOCROMOCITOMA<|>EVENT<|>Feocromocitoma is a type of tumor that arises from the adrenal glands and is often associated with MEN2 syndromes, particularly MEN2A and MEN2B.)\n##\n(\"entity\"<|>CARCINOMA MEDULAR<|>EVENT<|>Carcinoma medular is a type of thyroid cancer that is often associated with mutations in the RET proto-oncogene and is a key feature of MEN2 syndromes.)\n##\n(\"entity\"<|>TIROGLOBULINA<|>EVENT<|>Tiroglobulina is a protein used as a tumor marker in the management of thyroid cancer, particularly in monitoring for recurrence.)\n##\n(\"entity\"<|>PET 18F-FDG<|>EVENT<|>PET 18F-FDG is a type of imaging test used to detect cancer and assess the metabolic activity of tumors, including differentiated thyroid cancers.)\n##\n(\"entity\"<|>CANCER DIFERENCIADO DE TIROIDES<|>EVENT<|>Cáncer diferenciado de tiroides refers to a group of thyroid cancers that are typically well-differentiated and include papillary and follicular thyroid cancers.)\n##\n(\"relationship\"<|>MEN2A<|>FEOCROMOCITOMA<|>Feocromocitoma is often a concurrent diagnosis in patients with MEN2A<|>7)\n##\n(\"relationship\"<|>MEN2A<|>CARCINOMA MEDULAR<|>Carcinoma medular is a common manifestation of MEN2A<|>8)\n##\n(\"relationship\"<|>FEOCROMOCITOMA<|>CARCINOMA MEDULAR<|>Feocromocitoma and carcinoma medular are both associated with MEN2 syndromes<|>6)\n##\n(\"relationship\"<|>TIROGLOBULINA<|>CANCER DIFERENCIADO DE TIROIDES<|>Tiroglobulina is used as a marker to monitor patients with differentiated thyroid cancer<|>7)\n##\n(\"relationship\"<|>PET 18F-FDG<|>CANCER DIFERENCIADO DE TIROIDES<|>PET 18F-FDG is utilized in the staging and monitoring of differentiated thyroid cancer<|>8)\n<|COMPLETE|>", "input": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": [{"role": "user", "content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: con MEN2B tienen mutaciones en línea germinal en el exón 16 (codón M918T) del oncogen RET. En cambio, la mutación del codón 634 da origen a MEN2A (opción B falsa).\n\nEl diagnóstico de feocromocitoma es concurrente con el de MEN2A en el 35% al 73% de los casos, y es la primera manifestación del síndrome en el 9% al 27% de los casos. En la Guía de carcinoma medular de la ATA 2015 se indica que los feocromocitomas se suelen diagnosticar en la tercera o cuarta década de la vida coincidiendo o siguiendo al diagnóstico del carcinoma medular. Dada su posible presencia en el momento del diagnóstico de carcinoma medular, se recomienda su cribado antes de cualquier procedimiento quirúrgico. Igualmente se recomienda iniciar cribado de feocromocitoma a edades tan tempranas como los 11 y 16 años, según la mutación causante del MEN. Por lo tanto, aunque es cierto que lo habitual es que se diagnostique después de que se haya diagnosticado el carcinoma medular, existen excepciones.\n\nLos niveles preoperatorios de calcitonina son útiles para predecir la extensión de la enfermedad en este momento y para planificar la intervención quirúrgica. En efecto, niveles de calcitonina superiores a 20, 50, 200 y 500 pg/ml se asocian respectivamente con metástasis ganglionares del compartimento central y lateral ipsilateral, del compartimento central contralateral, del compartimento lateral contralateral y con metástasis a distancia. En cambio, valores inferiores a 10 pg/ml predicen una supervivencia a 10 años de un 97,7%.\n\nReferencias:\n- Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS). The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775-83.\n- Eng C, Smith DP, Mulligan LM, Nagai MA, Healey CS, Ponder MA, et al. Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours. Hum Mol Genet. 1994;3:237-41.\n- Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2655-63.\n- Marx SJ, Wells SA. Multiple Endocrine Neoplasia. Cap. 41. 12.ª ed, Williams. Textbook of Endocrinology. p. 1753.\n- Modigliani E, Cohen R, Campos JM, Conte-Devolx B, Maes B, Boneu A, et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol (Oxf). 1998;48:265-73.\n- Wells SA, Asa SL, Dralle H, Elisei R, Evan DB, Gagel RF, et al. Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid. 2015;25(6):567-610.\n\n## 44. En relación con la utilización de la PET con 18F-FDG en los carcinomas diferenciados de tiroides, indique cuál de las siguientes afirmaciones es cierta:\n\nA. La PET 18F-FDG tiene gran valor en la estadificación inicial de estos tumores.\nB. Una alta captación de FDG por parte de las metástasis de estos tumores predice una mala respuesta al tratamiento con I-131.\nC. La PET 18F-FDG debería ser utilizada en el seguimiento de la mayoría de estos tumores.\nD. La sensibilidad de la PET 18F-FDG para detectar posibles metástasis de estos tumores no se modifica con el estímulo con TSH.\n\n## COMENTARIO\n\nEn la guía de la ATA de manejo del cáncer diferenciado de tiroides se establece una serie de recomendaciones para la utilización de la PET 18F-FDG en el seguimiento del cáncer de tiroides. Establece que debe considerarse su utilización en caso de pacientes con alto riesgo de recidiva con niveles de tiroglobulina (TG) elevados (en general > 10 ng/ml) con rastreos con I-131 negativos.\n\nIgualmente se indica que se puede considerar la utilización de la PET 18F-FDG en:\n\n1. Como parte inicial de la estadificación en tumores pobremente diferenciados o carcinomas invasivos de células de Hürthle.\n2. Como herramienta pronóstica en pacientes con enfermedad metastásica para\n######################\nOutput:"}, {"role": "assistant", "content": "(\"entity\"<|>MEN2B<|>EVENT<|>MEN2B is a genetic condition characterized by mutations in the RET proto-oncogene, specifically in exon 16, leading to various endocrine tumors.)\n##\n(\"entity\"<|>MEN2A<|>EVENT<|>MEN2A is a genetic syndrome associated with mutations in the RET proto-oncogene, often presenting with pheochromocytoma and medullary thyroid carcinoma.)\n##\n(\"entity\"<|>ATA<|>ORGANIZATION<|>The American Thyroid Association (ATA) provides guidelines for the diagnosis and management of thyroid cancer, including medullary thyroid carcinoma.)\n##\n(\"entity\"<|>NANETS<|>ORGANIZATION<|>The North American Neuroendocrine Tumor Society (NANETS) is an organization that develops consensus guidelines for the management of neuroendocrine tumors.)\n##\n(\"entity\"<|>CHEN H<|>PERSON<|>Chen H is a researcher involved in the development of guidelines for neuroendocrine tumors, including pheochromocytoma and medullary thyroid cancer.)\n##\n(\"entity\"<|>SIPPEL RS<|>PERSON<|>Sippel RS is a researcher who contributed to the NANETS guidelines for neuroendocrine tumors.)\n##\n(\"entity\"<|>O'DORISIO MS<|>PERSON<|>O'Dorisio MS is a researcher who has contributed to the guidelines for the management of neuroendocrine tumors.)\n##\n(\"entity\"<|>VINIK AI<|>PERSON<|>Vinik AI is a researcher involved in the consensus guidelines for neuroendocrine tumors.)\n##\n(\"entity\"<|>LLOYD RV<|>PERSON<|>Lloyd RV is a researcher who has contributed to the guidelines for the management of neuroendocrine tumors.)\n##\n(\"entity\"<|>PACAK K<|>PERSON<|>Pacak K is a researcher involved in the development of guidelines for neuroendocrine tumors.)\n##\n(\"entity\"<|>MULLIGAN LM<|>PERSON<|>Mulligan LM is a researcher who has contributed to the understanding of RET mutations in multiple endocrine neoplasia.)\n##\n(\"entity\"<|>MARX SJ<|>PERSON<|>Marx SJ is a researcher who has written about multiple endocrine neoplasia and its management.)\n##\n(\"entity\"<|>WELLS SA<|>PERSON<|>Wells SA is a researcher who has contributed to the guidelines for the management of medullary thyroid carcinoma.)\n##\n(\"relationship\"<|>MEN2B<|>MEN2A<|>MEN2B and MEN2A are both genetic syndromes associated with mutations in the RET proto-oncogene, affecting endocrine function<|>7)\n##\n(\"relationship\"<|>ATA<|>NANETS<|>Both ATA and NANETS provide guidelines and recommendations for the management of neuroendocrine tumors and related conditions<|>6)\n##\n(\"relationship\"<|>CHEN H<|>NANETS<|>Chen H is a contributor to the NANETS guidelines for neuroendocrine tumors<|>8)\n##\n(\"relationship\"<|>SIPPEL RS<|>NANETS<|>Sippel RS is a contributor to the NANETS guidelines for neuroendocrine tumors<|>8)\n##\n(\"relationship\"<|>O'DORISIO MS<|>NANETS<|>O'Dorisio MS is a contributor to the NANETS guidelines for neuroendocrine tumors<|>8)\n##\n(\"relationship\"<|>VINIK AI<|>NANETS<|>Vinik AI is a contributor to the NANETS guidelines for neuroendocrine tumors<|>8)\n##\n(\"relationship\"<|>LLOYD RV<|>NANETS<|>Lloyd RV is a contributor to the NANETS guidelines for neuroendocrine tumors<|>8)\n##\n(\"relationship\"<|>PACAK K<|>NANETS<|>Pacak K is a contributor to the NANETS guidelines for neuroendocrine tumors<|>8)\n##\n(\"relationship\"<|>MULLIGAN LM<|>NANETS<|>Mulligan LM is a contributor to the NANETS guidelines for neuroendocrine tumors<|>8)\n##\n(\"relationship\"<|>MARX SJ<|>ATA<|>Marx SJ has contributed to the understanding and management of multiple endocrine neoplasia, which is relevant to ATA guidelines<|>5)\n##\n(\"relationship\"<|>WELLS SA<|>ATA<|>Wells SA has contributed to the guidelines for the management of medullary thyroid carcinoma, which is under the purview of ATA<|>6)\n<|COMPLETE|>"}]}